Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs TKO Group Holdings Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while TKO Group Holdings Inc trades at $173.56 (market cap $12.60B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.83% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and TKO Group Holdings Inc for 31 Days on average.
| KYMR | TKO | |
|---|---|---|
Market Cap | $8.88B | $12.60B |
Volume | 1,028,790 | 725,577 |
Sector | Health | Media |
52-Week High | $127.31 | $224.96 |
52-Week Low | $55.80 | $172.38 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $8.27B | $16.96B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TKO trades at $173.86, near its 52-week low of $174.58, reflecting recent bearish technical pressure. The stock shows mixed earnings performance, with a Q2 2026 EPS miss but raised full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though high P/E of 60.48 suggests premium valuation. A dividend of $0.79 is scheduled for September 2026.
Outlook remains cautiously optimistic due to strong media rights and franchise value, but high valuation and technical weakness pose near-term risks. Analyst consensus is strongly bullish with a $227 price target, indicating significant upside potential if execution meets expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
